Why the study?
How do cytochrome allelic variants (CYP2C19 and CYP3A4/5) impact clopidogrel metabolism and clinical outcomes in patients with acute coronary syndrome?
Population
Patients with acute coronary syndrome and heart attacks
Design
Review
Authors
Loading...
Genetic CYP variations may modify clopidogrel response in ACS; leaves open whether testing improves outcomes.
How do cytochrome allelic variants (CYP2C19 and CYP3A4/5) impact clopidogrel metabolism and clinical outcomes in patients with acute coronary syndrome?
Inter-individual polymorphisms in CYP enzymes, particularly CYP2C19 and CYP3A4/5, may significantly impact clopidogrel metabolism and clinical outcomes in ACS patients, potentially explaining variable responses to dual therapy with proton pump inhibitors.
Mohammed Jarrar (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: